CN104126666A - 一种含有南极磷虾油的调制乳 - Google Patents
一种含有南极磷虾油的调制乳 Download PDFInfo
- Publication number
- CN104126666A CN104126666A CN201410366020.0A CN201410366020A CN104126666A CN 104126666 A CN104126666 A CN 104126666A CN 201410366020 A CN201410366020 A CN 201410366020A CN 104126666 A CN104126666 A CN 104126666A
- Authority
- CN
- China
- Prior art keywords
- krill oil
- antarctic krill
- modulation breast
- milk
- mass parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940106134 krill oil Drugs 0.000 title claims abstract description 41
- 235000013336 milk Nutrition 0.000 title claims abstract description 7
- 239000008267 milk Substances 0.000 title claims abstract description 7
- 210000004080 milk Anatomy 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000000194 fatty acid Substances 0.000 claims abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 8
- 229930195729 fatty acid Natural products 0.000 claims abstract description 8
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 5
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 4
- 210000000481 breast Anatomy 0.000 claims description 31
- -1 fatty acid ester Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical class C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229930182558 Sterol Chemical class 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Chemical class CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- 239000011648 beta-carotene Chemical class 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Chemical class CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical class CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003316 Vitamin D Chemical class 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 235000020247 cow milk Nutrition 0.000 claims description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000011707 mineral Chemical class 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229940072033 potash Drugs 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 235000020201 recombined milk Nutrition 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 150000003432 sterols Chemical class 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Chemical class 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract description 31
- 235000013793 astaxanthin Nutrition 0.000 abstract description 31
- 239000001168 astaxanthin Substances 0.000 abstract description 31
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract description 31
- 229940022405 astaxanthin Drugs 0.000 abstract description 31
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 18
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 18
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 18
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 18
- 210000004556 brain Anatomy 0.000 abstract description 14
- 150000003904 phospholipids Chemical class 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 239000003921 oil Substances 0.000 abstract description 6
- 235000019198 oils Nutrition 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 5
- 235000021323 fish oil Nutrition 0.000 abstract description 5
- 241000195493 Cryptophyta Species 0.000 abstract description 4
- 238000004945 emulsification Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000006014 omega-3 oil Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 210000004958 brain cell Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 5
- 241000239366 Euphausiacea Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 2
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000005409 aflatoxin Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical group 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- IJAGKEKOJGWANE-KCBWXHRDSA-N (3r,4r,5r)-5-[(2s,3r)-4-[(e)-2-carboxyethenyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carbonyl]oxy-3,4-dihydroxycyclohexene-1-carboxylic acid Chemical compound O[C@@H]1[C@H](O)C=C(C(O)=O)C[C@H]1OC(=O)[C@@H]1C(C(\C=C\C(O)=O)=CC=C2O)=C2O[C@@H]1C1=CC=C(O)C(O)=C1 IJAGKEKOJGWANE-KCBWXHRDSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000505673 Scintilla Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- IJAGKEKOJGWANE-UHFFFAOYSA-N brainic acid Natural products OC1C(O)C=C(C(O)=O)CC1OC(=O)C1C(C(C=CC(O)=O)=CC=C2O)=C2OC1C1=CC=C(O)C(O)=C1 IJAGKEKOJGWANE-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003397 luteinic effect Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种含有南极磷虾油的调制乳,将南极磷虾油0.001~2质量份,添加到生乳70~99.99质量份中,经过乳化、均质、灭菌制得。磷虾油作为omega3脂肪酸强化剂添加到生乳中,磷虾油自身特有的乳化性,无需添加乳化剂或者少量添加乳化剂。南极磷虾油有丰富的omega3脂肪酸,即二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)、还有磷脂、虾青素等天然抗氧化剂,且南极磷虾油中富含的不饱和脂肪酸是以磷脂型态结合的脂肪酸,其人体吸收率远远高于鱼油或者藻油。长期饮用保护心脑血管、健脑益智、延缓衰老、提高免疫力,特别适合儿童、脑力劳动者和中老年人。
Description
技术领域
本发明涉及一种含有南极磷虾油的调制乳。
技术背景
南极磷虾油源自南极磷虾,南极磷虾生活在南极寒带无污染水域。南极磷虾油富含以二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)为代表的Omega-3多不饱和脂肪酸、磷脂、虾青素等活性物质,是珍贵的保健品原料。其不饱和脂肪酸是以磷脂型态结合omega3(EPA、DHA),使得omega3多不饱和脂肪酸更加稳定,且更易于被人体吸收。
目前,市场上的相关Omega 3产品主要来源于鱼油和海藻油,鱼油和藻油中的EPA和DHA,它们主要以脂肪酸乙酯或甘油三酯形式存在;而南极磷虾油中的EPA和DHA主要以磷脂形式存在,磷脂更益于人体的吸收。研究发现,利用南极磷虾油对肥胖人群进行实验,发现磷虾油能增加肥胖人群血液中EPA和DHA的浓度。在连续服用磷虾油(2g/d)四周的人血浆中EPA和DHA的浓度增幅明显高于服用鲱鱼油(2g/d)的增幅及服用橄榄油(2g/d)的增幅,说明了磷虾油在人体中具有很好的吸收性。且经测定,磷虾油没有产生任何毒副作用。
南极磷虾油已证明有如下保健功效: 1 降低胆固醇、预防脑溢血、脑血栓;
2 降低血液黏稠度、促进血液循环,预防高血压; 3 健脑益智,活跃思维,预防老年痴呆症;
4保护大脑神经细胞增进记忆; 5抗疲劳,提高免疫力; 6缓解痛风和类风湿关节炎; 7抗氧化,延缓衰老; 8缓解妇女经期前的不适症状;
在本发明的产品中,所述的南极磷虾油是以南极磷虾为原料,通过干燥、低温萃取、浓缩等工艺而得到,其质量符合卫生部新资源食品2013年第?号公告,其中磷脂含量≥40%,DHA含量≥5.5%,EPA含量≥15%,虾青素含量≥50ppm。
磷脂
磷脂也称磷脂类、磷脂质,是含有磷酸的脂类,属于复合脂。磷脂组成生物膜的主要成分,分为甘油磷脂与鞘磷脂两大类,分别由甘油和鞘氨醇构成。磷脂为两性分子,一端为亲水的含氮或磷的尾,另一端为疏水(亲油)的长烃基链。由于此原因,磷脂分子亲水端相互靠近,疏水端相互靠近,常与蛋白质、糖脂、胆固醇等其他分子共同构成脂双分子层,即细胞膜的结构。是细胞中所有膜状构造的主要成分。
磷脂是含磷酸的复合脂质。包括磷酸甘油酯(又称甘油磷酸酯)和鞘磷脂两类。生物体的重要组分,如动物的脑、肝、红细胞和卵黄等以及植物的种子含量较多,磷脂是细胞膜和各种细胞器(线粒体、内质网、细胞核、高尔基器、叶绿体等)膜的重要组分,几乎细胞所含有的全部磷脂都集中在生物膜中。生物膜的许多特性,如作为膜内外物质的通透性屏障,膜内外物质的交换,信息传递,神经脉冲的传导等都与磷脂和其他膜脂有关。磷酸甘油酯的主链是甘油,甘油的第三个羟基被磷酸酯化,另外两个羟基被脂肪酸酯化,磷酸基团又与各种结构不同的小分子化合物相连接。两个长碳氢链(脂肪酸链)具有非极性特性,甘油分子的第三个羟基与磷酸形成的酯键是有极性的;所以这类化合物是亲水脂两性分子。常见的磷酸甘油酯有磷脂酰胆碱(卵磷脂)、磷脂酰乙醇胺(脑磷脂)等。鞘磷脂的主链是鞘氨醇(含氨基的长链醇类化合物),脂肪酸以酰胺键连接在它的氨基上,磷酸以酯键连接在它的1-羟基上。鞘磷脂也是亲水脂两性分子,是高等动物神经组织中含量最丰富的鞘脂类(鞘氨醇是鞘磷脂的主要成分,故亦属于鞘脂类)。磷脂能在生物体内合成并快速地周转。
磷脂主要作用之一是:乳化作用 分解过高的血脂和过高的胆固醇,清扫清管,使血管循环顺畅,是公认为血管清道夫,还可以使中性脂肪和血管中积压的胆固醇乳化为对人体无害的微分子状态,并溶解于水中排出体外,同时阻止多余脂肪在血管壁沉积,缓解心脑血管的压力。磷脂之所以防治现代文明病,其根本原因之一,就是在于它具有强大的乳化作用。
磷脂主要作用之二:增智
人体神经细胞和大脑细胞是由磷脂为主所构成的细胞薄膜包覆,磷脂不足会导致薄膜受损,造成智力减退,精神紧张。而磷脂中含的乙酰进入人体内与胆碱结合,构成乙酰胆碱。而乙酰胆碱恰恰是各种神经细胞和大脑细胞间传递信息的载体。可以加快神经细胞和大脑细胞间信息传递的速度,增加记忆力,预防老年痴呆。
磷脂主要作用之三:活化细胞 磷脂是细胞膜的重要组成部分,肩负着细胞内外物质交换的重任。如果人每天所消耗的磷脂得不到补充,细胞就会处于营养缺乏状态,失去活力。 人的肝脏能合成一些磷脂,但大部分是从饮食中摄取的。特别是三四十岁以后,但是磷脂的活性以25度左右最有效,温度超过摄氏50度后,磷脂活性会大部分失去。因此本人建议健康的人亚健康的人都可以食用磷脂,会给你带来出乎意料的效果。
DHA
DHA,二十二碳六烯酸,俗称脑黄金,是一种对人体非常重要的多不饱和脂肪酸,属于Omega-3不饱和脂肪酸家族中的重要成员。DHA是神经系统细胞生长及维持的一种主要元素,是大脑和视网膜的重要构成成分,在人体大脑皮层中含量高达20%,在眼睛视网膜中所占比例最大,约占50%,因此,对胎婴儿智力和视力发育至关重要。
1.DHA可以促进胎儿大脑发育
DHA 能优化胎儿大脑锥体细胞的磷脂的构成成分。尤其胎儿满 5 个月后,如人为地对胎儿的听觉、视觉、触觉进行刺激,会引起胎儿大脑皮层感觉中枢的神经元增长更多的树突,这就需要母体同时供给胎儿更多的 DHA 。
2.DHA可以促进视网膜光感细胞的成熟
DHA 不仅对胎儿大脑发育有重要影响,而且对视网膜光感细胞的成熟有重要作用。孕妇在孕期可通过摄入富含DHA食物 ,然后输送到胎儿大脑和视网膜,使那里的神经细胞成熟度提高。
3.DHA可以增进大脑细胞之发育
在大脑皮质中,DHA是神经传导细胞的主要成份,亦是细胞膜形成的主要成份,大部分的DHA不会被胃液所消化,而直接进入血液,被肝或脑等器官吸收,而EPA及次亚麻油酸却不被吸收通过血脑屏障被脑吸收。
4.DHA可以用于癌症治疗
科学家发现,深海鱼中所富含的ω-3脂肪酸和二十二碳六烯酸及其衍生物在机体中能够杀死神经母细胞瘤癌细胞。在该研究中,科学家使DHA从神经系统中转移到髓母细胞瘤中,当DHA在细胞内代谢后,再对细胞中的副产物进行分析。随后科学家研究了DHA及其衍生物对癌细胞生长的影响。研究结果表明,DHA杀死了所有的癌细胞,而且由DHA衍生物产生的毒性比DHA本身更能有效地杀死癌细胞。这表明,DHA或可成为一种新的治疗神经母细胞瘤或其他癌症的新药物。这项研究对治疗癌症有重要意义,由于DHA在保护人体健康上的重要作用,未来可根据DHA及其衍生物研制一类新的抗癌药物。
5.DHA可以抑制发炎
DHA会抑制发炎前驱物质的形成,所以具有消炎作用。
6.DHA可以降低血脂肪、预防心脏血管疾病
DHA可降低血液中三酸甘油脂、胆固醇及预防血栓的形成。
7.DHA可以改善老人痴呆
由于随着年龄的增长,脑中的DHA就会逐渐减少,也就是说容易引起脑部功能的退化。事实上,脑细胞在二至三岁前会不断的成长,长大成人后,则会逐渐减少,根据调查,在二十至三十岁时,脑细胞会以十万个的比率逐渐减少,虽然如此,DHA仍具有使剩下的脑细胞活性化的力量,充分地提高记忆及学习能力。
EPA
EPA 是 Eicosapntemacnioc Acid 即二十碳五烯酸的英文缩写, EPA属于omega3系列多不饱和脂肪酸,是人体自身不能合成但又不可缺少的重要营养素,因此称为人体必需脂肪酸。虽然亚麻酸在人体内可以转化为EPA,但此反应在人体中的速度很慢且转化量很少,远远不能满足人体对EPA的需要,因此必须从食物中直接补充。 EPA具有帮助降低胆固醇和甘油三酯的含量,促进体内饱和脂肪酸代谢。从而起到降低血液粘稠度,增进血液循环,提高组织供氧而消除疲劳。防止脂肪在血管壁的沉积,预防动脉粥样硬化的形成和发展、预防脑血栓、脑溢血、高血压等心血管疾病。
虾青素
天然虾青素是迄今为止人类发现自然界最强的抗氧化剂。它的效果被确认是维生素C的功效的6000倍;是维生素E的1000倍;天然 β - 胡萝卜素的10倍; 葡萄籽的17倍;黄体素的200倍;OPC的150倍;Q10的60倍;茶多酚的200倍;番茄红素的7倍。
虾青素保健功效如下:
1.眼和中枢神经系统的保护作用
人类视网膜和中枢神经系统(脑)富含不饱和脂肪酸,因此,氧化产生的自由基很容易使其发生过氧化损伤。有研究表明,虾青素很容易通过血脑屏障和细胞膜,能有效地防止视网膜的氧化和感光细胞的损伤,以及对中枢神经系统尤其是对大脑起到保护作用,从而有效治疗缺血-再灌注损伤、脊髓损伤、帕金森综合征、Alzheimer综合征等中枢神经系统损伤。尤其是视网膜黄斑变性效果较叶黄素更加显著。
2.防紫外线辐射
众所周知,紫外线辐射是导致表皮光老化和皮肤癌的重要原因。研究表明,虾青素对谷氨酰胺转胺酶(transglutaminase)具有特殊作用,能够在皮肤受光照时消耗腐胺,口服虾青素对腐胺积累的抑制作用比口服维生素A更强。因此,虾青素的强抗氧化性可能使它成为潜在的光保护剂,有效清除引起皮肤老化的自由基,保护细胞膜和线粒体膜免受氧化损伤,用于阻止皮肤光老化。
3.预防心血管疾病
动脉硬化及相关心血管疾病的临床研究表明,低密度脂蛋白(LDL)的氧化是导致动脉硬化的重要原因。人体中LDL浓度越高,加之血小板沉积使血管变细阻碍血流速度,人体患动脉硬化的风险就越大。而血液中高密度脂蛋白(HDL)则有相反的作用,它可以阻止动脉硬化的发生。在人体血液中,虾青素由极低密度脂蛋白(VLDL)、LDL和HDL携带。体外和临床试验证明每人口服3.6mg/d虾青素,连续2周,能预防LDL的氧化。另外,有动物研究表明,虾青素在体内具有显著升高HDL和降LDL的功效,其中HDL可由原来的49.7±3.6mg/dL增加至66.5±5.1mg/dL,因此推测虾青素能减轻载脂蛋白的氧化,可用来预防动脉硬化、冠心病和缺血性脑损伤。不同于一般降低LDL的药物,每天服用1.8、3.6、14.4和21.6mg虾青素连续2周后,LDL氧化的时间分别被延长了5.0%、26.2% 、42.3%和30.7% ;从而可预防动脉粥样硬化的发生。
4.增强免疫力
虾青素能显著影响动物的免疫功能,在有抗原存在时,能明显促进脾细胞产生抗体的能力,增强T细胞的作用,刺激体内免疫球蛋白的产生。虾青素还能够部分恢复年老小鼠的体液免疫系统,其中可使小鼠体内的IgM、IgA和IgG分别都增加至10mol/L,表明在抗原入侵初期,它能增强特异性体液免疫反应。另外,虾青素还可以增强小鼠释放白细胞介素-Iα和肿瘤坏死因子α的能力,其作用比β-胡萝卜素和角黄素强得多。由此认为,虾青素有很强的诱导细胞分裂的活性,具有重要的免疫调节作用。
5.缓解运动疲劳,增强机体能量代谢
当机体运动时肌肉会释放自由基,这些自由基若不被抗氧化剂及时处理,就会产生氧化压力,致使肌肉酸痛或肌肉组织的损伤。研究表明,虾青素可以作为一种抗氧化剂抑制自由基对机体的氧化损害作用。另外,口服虾青素还可以强化需氧代谢,增加肌肉力量和肌肉耐受力,迅速缓解运动疲劳,减轻剧烈运动后产生的迟发性肌肉疼痛。主要表现在:4mg/天,6个月后可增幅体力40%。4mg/天,2周后可延长持续运动的时间20%,以及减少运动后的乳酸堆积28.6%。
6.抗炎抗感染特性
关节疼痛和关节炎通常是自由基导致的氧化损伤所致。虾青素较强的抗氧化特性有助于抑制自由基,减少其对关节的氧化损害。
7.抑制肿瘤
Tanaka等的研究表明,给实验大鼠和小鼠饲喂虾青素100~500mg/kg,能显著抑制化学物诱导的初期癌变,对暴露于致癌物质中的上皮细胞具有抗增殖作用和强化免疫功能的作用,而且这种效应存在剂量-效应关系。与对照组相比,高剂量组(500mg/kg)的肿瘤发生率和肿瘤大小明显低于对照组和低剂量组。因此推测虾青素具有显著的抗癌特性。虾青素还能诱导肝脏中的转移酶,显著抑制小鼠膀胱癌、大鼠口腔癌和结肠癌、胃癌,其作用效果要比β-胡萝卜素更为明显。另外,虾青素还能预防黄曲霉毒素的致癌性,对减少黄曲霉毒素诱导的肝肿瘤细胞的数量和体积效果良好。虾青素的抗癌机制已被认为它与细胞膜的稳定性和蛋白质基因表达有关,通过改变膜稳定性和基因表达数量来调节细胞间通讯,从而提高细胞间的平衡能力,维持细胞的正常功能。
8.抑制糖尿病肾病
糖尿病人70%会在5年内发展为肾病损害,虾青素是迄今为止发现的唯一可以有效阻止糖尿病肾病损的物质,虾青素主要是通过直接保护肾小球基底膜、阻止因高血糖产生的自由基来破坏基底膜;此外,还可以对抗肾小管上皮细胞的自由基,保护葡萄糖及磷的在肾小管细胞的正常转运,从而保存ATP及钠-钾ATP酶这些重要物质,确保肾脏血流不受影响,减少蛋白尿的产生。研究证实:8mg虾青素,8周时间可显著减少尿蛋白70%。
在我国,南极磷虾属尚未规模开发的资源,还没有自主知识产权的磷虾产品面市,且在我国专利保护中仅有有关磷虾油提取方面的专利,尚未见磷虾油乳品的相关报道。
目前,市场上的相关Omega 3调制乳中的omega 3脂肪酸多以鱼油和藻油为主,而南极磷虾油来自无污染的南极海域,其不饱和脂肪酸是以磷脂型态结合,比鱼油和藻油人体吸收率稳定性好、稳定性也更好。现代消费者越来越崇尚天然、绿色和健康,因此,添加南极磷虾油的营养调制乳将会有更广阔的发展空间。
发明内容
本发明的目的是提供一种含有南极磷虾油的调制乳。
本发明包括下述方面:
1.一种含有南极磷虾油的调制乳,其原料配方中包含:
生乳 70~99.999质量份
南极磷虾油 0.001~2质量份
2.根据项1所述的生乳指普通牛乳或者羊乳中的一种或者两种,包括全脂、脱脂和半脱脂;或用奶粉、奶油、水解蛋白、乳清粉或生牛乳、生羊乳的其他组分分配而成的还原乳。
3.根据项1-2所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有稳定剂0~0.3质量份,选自抗坏血酸、抗坏血酸钠、磷酸三钠、磷酸二氢钠、柠檬酸钠、柠檬酸钾、碳酸钾、碳酸氢钾、碳酸钠、卡拉胶、阿拉伯胶、瓜尔胶、果胶、海藻酸钠、琼脂、微晶纤维素、槐豆胶的混合物,比例是任意比例。
4.根据项1-3所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有乳化剂0~0.3质量份,选自蔗糖酸脂肪酸酯、单甘油脂肪酸酯、山梨糖醇脂、大豆磷脂、月桂酸单甘油酯、丙二醇脂肪酸酯的混合物,比例是任意比例。因磷虾油中含有大量的磷脂,自身具有乳化性,因此可不必另外添加乳化剂,或者可根据生乳的特性或添加其他营养物质的特性,酌情添加。
5.根据项1-4所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有甜味剂0~10质量份,选自葡萄糖、果糖、蔗糖、麦芽糖、乳糖、三氯蔗糖、安塞蜜、糖精钠、赤藓糖醇、木糖醇、山梨糖醇、甘露糖醇、麦芽糖醇、异麦芽糖醇等混合物,其比例是任意比例。
6. 根据项1-5所述的含有南极磷虾油的调制乳,其特征在于:所诉调制乳还含有其它营养素0~1质量份,选自维生素A、维生素E、维生素D、牛黄酸、低聚果糖、低聚半乳糖、低聚异麦芽糖、叶黄素、叶黄素酯、β-胡萝卜素、甾醇、甾醇酯、矿物盐中的混合物,其比例是任意比例。
7.根据权利要求1-6所述的含有南极磷虾油的调制乳,其特征在于:所诉调制乳还含有食用香精0~0.3质量份,所诉的食用香精可为天然香精、天然等同香精或人工香精。比如:水果味香精、奶味香精、花味香精、茶香精等一种或两种以上以任意比例组成的混合物。
只要不影响本发明的目的,本发明的调制乳的生产可以采用任何本技术领域的常规工艺。
本发明的产品突破了原有调味乳的机构和比例,增加了产品的新品种,补充了不饱和脂肪酸、磷脂,对于提高记忆力和保护心脑血管均具有好处,而且,磷虾油中含有的高效抗氧化剂虾青素,具有抗氧化延缓衰老等功效,使得产品营养更丰富,满足了现代消费者的营养需求。
另外,本发明的调制乳因为还可以添加其它营养物质,使得产品营养需求分明,可以满足不同人群的需求。本发明的产品可以满足儿童、青少年、上班族、中老年人等多方面人群的需求,具有很强的市场需求。
具体实施方式
下面以具体实施例对本发明的内容做进一步的说明,实施例不以任何方式限制本发明的内容。
实施例1
实施例2
实施例3
实施例4
实施例5
实施例6
实施例7
实施例8
Claims (7)
1.一种含有南极磷虾油的调制乳,其特征在于其原料配方中包含:
南极磷虾油0.001~2质量份,
生乳 70~99.99质量份。
2.根据权利要求1所述的含有南极磷虾油的调制乳,其特征在于:生乳指普通牛乳或者羊乳中的一种或者两种,包括全脂、脱脂和半脱脂;或用奶粉、奶油、水解蛋白、乳清粉或生牛乳、生羊乳的其他组分分配而成的还原乳。
3.根据权利要求1-2所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有稳定剂0~0.3质量份,选自抗坏血酸、抗坏血酸钠、磷酸三钠、磷酸二氢钠、柠檬酸钠、柠檬酸钾、碳酸钾、碳酸氢钾、碳酸钠、卡拉胶、阿拉伯胶、瓜尔胶、果胶、海藻酸钠、琼脂、微晶纤维素、槐豆胶的混合物,比例是任意比例。
4.根据权利要求1-3所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有乳化剂0~0.3质量份,选自蔗糖酸脂肪酸酯、单甘油脂肪酸酯、山梨糖醇脂、大豆磷脂、月桂酸单甘油酯、丙二醇脂肪酸酯的混合物,比例是任意比例。
5.根据权利要求1-4所述的含有南极磷虾油的调制乳,其特征在于:所述的调制乳含有甜味剂0~10质量份,选自葡萄糖、果糖、蔗糖、麦芽糖、乳糖、三氯蔗糖、安塞蜜、糖精钠、赤藓糖醇、木糖醇、山梨糖醇、甘露糖醇、麦芽糖醇、异麦芽糖醇等混合物,其比例是任意比例。
6.根据权利要求1-5所述的含有南极磷虾油的调制乳,其特征在于:所诉调制乳还含有其它营养素0~1质量份,选自维生素A、维生素D、牛黄酸、低聚果糖、低聚半乳糖、低聚异麦芽糖、叶黄素、叶黄素酯、β-胡萝卜素、甾醇、甾醇酯、矿物盐中的混合物,其比例是任意比例。
7.根据权利要求1-5所述的含有南极磷虾油的调制乳,其特征在于:所诉调制乳还含有食用香精0~1质量份,所诉的食用香精可为天然香精、天然等同香精或人工香精。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410366020.0A CN104126666A (zh) | 2014-03-26 | 2014-07-29 | 一种含有南极磷虾油的调制乳 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410116238.0 | 2014-03-26 | ||
| CN201410116238 | 2014-03-26 | ||
| CN201410366020.0A CN104126666A (zh) | 2014-03-26 | 2014-07-29 | 一种含有南极磷虾油的调制乳 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104126666A true CN104126666A (zh) | 2014-11-05 |
Family
ID=51799718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410366020.0A Pending CN104126666A (zh) | 2014-03-26 | 2014-07-29 | 一种含有南极磷虾油的调制乳 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104126666A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
| CN106922825A (zh) * | 2017-04-07 | 2017-07-07 | 山东阳春羊奶乳业有限公司 | 一种调制乳专用稳定剂及其制备方法 |
| CN107567331A (zh) * | 2015-03-31 | 2018-01-09 | 费森尤斯卡比德国有限公司 | 用于肠胃外给药的乳液 |
| CN107897466A (zh) * | 2017-11-09 | 2018-04-13 | 山东天地健生物工程有限公司 | 一种南极磷虾油夹心型凝胶糖果及其制备方法 |
| CN109198339A (zh) * | 2018-10-22 | 2019-01-15 | 辽渔南极磷虾科技发展有限公司 | 一种南极磷虾油饮品 |
| CN110236198A (zh) * | 2019-06-18 | 2019-09-17 | 宁波仙健海嘉生物科技有限公司 | 富含Omega-3不饱和脂肪酸的口服乳剂及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102144669A (zh) * | 2011-04-14 | 2011-08-10 | 内蒙古蒙牛乳业(集团)股份有限公司 | 含有dha藻油的调制乳及其生产方法 |
| CN103445186A (zh) * | 2013-09-02 | 2013-12-18 | 青岛贝尔特生物科技有限公司 | 一种婴幼儿专用海洋蛋白粉及制备方法 |
| WO2014013335A2 (en) * | 2012-07-17 | 2014-01-23 | Aker Biomarine As | Concentration of omega-3 polyunsaturated fatty acids in krill oil |
-
2014
- 2014-07-29 CN CN201410366020.0A patent/CN104126666A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102144669A (zh) * | 2011-04-14 | 2011-08-10 | 内蒙古蒙牛乳业(集团)股份有限公司 | 含有dha藻油的调制乳及其生产方法 |
| WO2014013335A2 (en) * | 2012-07-17 | 2014-01-23 | Aker Biomarine As | Concentration of omega-3 polyunsaturated fatty acids in krill oil |
| CN103445186A (zh) * | 2013-09-02 | 2013-12-18 | 青岛贝尔特生物科技有限公司 | 一种婴幼儿专用海洋蛋白粉及制备方法 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107567331A (zh) * | 2015-03-31 | 2018-01-09 | 费森尤斯卡比德国有限公司 | 用于肠胃外给药的乳液 |
| CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
| CN106922825A (zh) * | 2017-04-07 | 2017-07-07 | 山东阳春羊奶乳业有限公司 | 一种调制乳专用稳定剂及其制备方法 |
| CN107897466A (zh) * | 2017-11-09 | 2018-04-13 | 山东天地健生物工程有限公司 | 一种南极磷虾油夹心型凝胶糖果及其制备方法 |
| CN109198339A (zh) * | 2018-10-22 | 2019-01-15 | 辽渔南极磷虾科技发展有限公司 | 一种南极磷虾油饮品 |
| CN110236198A (zh) * | 2019-06-18 | 2019-09-17 | 宁波仙健海嘉生物科技有限公司 | 富含Omega-3不饱和脂肪酸的口服乳剂及其制备方法 |
| CN110236198B (zh) * | 2019-06-18 | 2024-02-09 | 宁波仙健海嘉生物科技有限公司 | 富含Omega-3不饱和脂肪酸的口服乳剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4699901B2 (ja) | 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質 | |
| ES2763958T3 (es) | Oligosacáridos de leche humana para mejorar los síntomas del estrés | |
| ES2682074T3 (es) | Fórmulas para lactantes que contienen ácido docosahexaenoico y luteína | |
| ES2875458T3 (es) | Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño | |
| ES2660416T3 (es) | Mezcla de lípidos para la nutrición de bebés | |
| JPH08205832A (ja) | 強化果物ジュース | |
| CN104126666A (zh) | 一种含有南极磷虾油的调制乳 | |
| RU2706963C2 (ru) | Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин | |
| US20060083824A1 (en) | Nutritional supplements for glucose intolerant individuals | |
| JPH08205769A (ja) | 強化又は補強したミルク又はミルク誘導製品 | |
| CN107495379A (zh) | 含有多不饱和脂肪酸、蛋白质及锰和/或钼的组合物 | |
| CN104427887A (zh) | 包含RRR-α生育酚和多不饱和脂肪酸的营养组合物 | |
| KR20200128656A (ko) | 리소포스파티딜콜린 조성물 | |
| KR20180075716A (ko) | 포만감 유발 조성물 | |
| EP3062789A1 (en) | Monoacylglycerols and fat-soluble nutrients for use in the treatment of maldigestion | |
| CN106061291A (zh) | 使用绿茶提取物来增加骨骼肌蛋白质合成的方法 | |
| WO2020237340A1 (pt) | Suplemento alimentar de alta-energia baseado em açúcares invertidos e produtos ergogênicos para uso em atividades físicas e seu processo de produção | |
| CN114222568A (zh) | 用于治疗和缓解疾病的极长链脂肪酸 | |
| Pham-Huy et al. | Food and lifestyle in health and disease | |
| González et al. | Infant Nutrition: Breast milk substitutes and gut-brain axis improved by microalgae | |
| CN104757535A (zh) | 黑枸杞减肥片(茶) | |
| KR20110119305A (ko) | 타우린, 비타민류, 로얄젤리, 홍삼, 구기자, 글루메이트 (탈지미강, 미베아) 및 애플 에센스를 주성분으로 함유하는 기능성 음료조성물 | |
| JP2009269864A (ja) | リン脂質結合型アラキドン酸増加剤 | |
| CN101156862A (zh) | 一种卵磷脂维生素e咀嚼片及其制备方法 | |
| TW201929849A (zh) | 癌症患者肌肉量減少之抑制組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141105 |